PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
May 21, 2026Clinical HypertensionOpen Access

Highlights of the 2026 Korean Society of Hypertension guidelines for the management of hypertension: what’s new and what has changed

View Full Paper
Ask AI
Bookmark
Share

Why the study?

To summarize the most important updates, underlying evidence, and key changes in the 2026 Korean Society of Hypertension guidelines, incorporating contemporary advances in hypertension diagnosis and management.

Design

Clinical practice guideline highlight

Key result

The 2026 Korean Society of Hypertension guidelines update hypertension management by incorporating isolated diastolic hypertension, cuffless blood pressure devices, new therapies, and intensive targets.

Discussion

Loading...

Member takes

Overview

May inform Korean hypertension practice with revised classification and monitoring; leaves open outcome validation in broader populations.

Key Points

  • To summarize the significant advancements and recommendations of the 2026 KSH guidelines for hypertension management.
  • Review of the newly incorporated recommendations in the KSH guidelines.
  • Focus on evidence supporting changes, including therapeutic options and management strategies.
  • Discussion of clinical applications of cuffless BP devices and updates on specific patient populations.
  • Isolation of diastolic hypertension as a blood pressure category has been added.
  • Introduction of new therapies like angiotensin receptor–neprilysin inhibitors and sodium–glucose cotransporter 2 inhibitors.
  • Revised BP targets for older adults and the emphasis on individualized treatment to enhance adherence.

Structured PICO

P
Population
Adults with hypertension, prehypertension, or at risk of hypertension in Korea, including specific subgroups (young adults, older adults, pregnant women, and patients with obesity, diabetes, chronic kidney disease, stroke, or heart failure).
I
Intervention
2026 Korean Society of Hypertension (KSH) guidelines for the management of hypertension, including lifestyle modifications, cuffless blood pressure monitoring, and pharmacological therapies (ARNI, SGLT2 inhibitors, non-steroidal MRAs, aldosterone synthase inhibitors, and single-pill combinations).

The 2026 KSH guidelines provide updated, evidence-based recommendations for hypertension management, notably incorporating cuffless BP monitoring, new pharmacological classes, and more intensive BP targets for high-risk populations.

Limitations

  • Accuracy concerns and lack of standardization for cuffless blood pressure devices.
  • Limited evidence supporting intensive blood pressure lowering in low-risk patients with diabetes.

Cite This Study

A 2026 study conducted a review in Hypertension. 2026 Korean Society of Hypertension guidelines was evaluated. The 2026 Korean Society of Hypertension guidelines update hypertension management by incorporating isolated diastolic hypertension, cuffless blood pressure devices, new therapies, and intensive targets.

synapsesocial.com/papers/6a0ea5b9be05d6e3efb60917https://doi.org/10.5646/ch.2026.32.e31
View Full Paper
Ask AI
Bookmark
Share